DYRK1B and ovarian cancer: In addition, ROS levels increased when Mirk kinase was inhibited and further increased when ovarian cancer cells were also treated with RAD001 (Fig.4C), showing similar effects of both Mirk depletion (11) and Mirk kinase inhibition by EHT5372.